Pfizer Past Earnings Performance
Past criteria checks 1/6
Pfizer has been growing earnings at an average annual rate of 19.4%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 16.3% per year. Pfizer's return on equity is 2.4%, and it has net margins of 3.6%.
Key information
19.4%
Earnings growth rate
19.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 16.3% |
| Return on equity | 2.4% |
| Net Margin | 3.6% |
| Next Earnings Update | 01 May 2024 |
Recent past performance updates
Recent updates
Pfizer: The Market Is Wrong
Apr 11Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns
Mar 18Pfizer: A Strong Buy Trading Below A 10 P/E Ratio
Mar 08Pfizer: A Value Trap, Not A Bargain
Feb 28Pfizer: Turnaround Is Gaining Momentum
Feb 21Is Pfizer (NYSE:PFE) A Risky Investment?
Feb 21
Pfizer Is A Great Investment Over The Next Decade; Buy
Feb 09Pfizer: Reviewing Q4 Earnings, FY24 Guidance - Why I Disagree With The Market
Jan 31Why I'm Avoiding 6%-Yielding Pfizer Stock
Jan 23Pfizer Is Part Of The 2024 Healthcare Sector Rally Cohort
Jan 12Pfizer's (NYSE:PFE) Dividend Will Be Increased To $0.42
Jan 10Pfizer: If You Missed The Pandemic Entry, Here's Another Chance
Jan 03Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase
Dec 26Eli Lilly Looks Overvalued, Buy Pfizer Instead
Dec 19Pfizer's (NYSE:PFE) Shareholders Will Receive A Bigger Dividend Than Last Year
Dec 18Revenue & Expenses BreakdownBeta
How Pfizer makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 58,496 | 2,134 | 13,836 | 10,679 |
| 01 Oct 23 | 68,537 | 10,469 | 13,575 | 11,420 |
| 02 Jul 23 | 77,943 | 21,494 | 13,393 | 11,435 |
| 02 Apr 23 | 92,951 | 29,035 | 13,258 | 11,621 |
| 31 Dec 22 | 100,330 | 31,366 | 12,200 | 11,428 |
| 02 Oct 22 | 99,878 | 29,953 | 11,325 | 11,260 |
| 03 Jul 22 | 101,275 | 29,481 | 10,032 | 11,243 |
| 03 Apr 22 | 92,433 | 25,410 | 9,400 | 10,667 |
| 31 Dec 21 | 81,288 | 22,413 | 9,562 | 10,360 |
| 03 Oct 21 | 68,877 | 19,485 | 9,714 | 9,972 |
| 04 Jul 21 | 55,119 | 12,236 | 11,676 | 9,589 |
| 04 Apr 21 | 46,084 | 9,032 | 11,454 | 9,184 |
| 31 Dec 20 | 41,651 | 6,630 | 11,418 | 8,709 |
| 27 Sep 20 | 32,334 | 212 | 11,006 | 8,084 |
| 28 Jun 20 | 34,737 | 6,977 | 10,565 | 7,727 |
| 29 Mar 20 | 38,137 | 9,427 | 11,637 | 7,716 |
| 31 Dec 19 | 40,905 | 10,707 | 12,766 | 7,721 |
| 29 Sep 19 | 53,039 | 16,211 | 13,755 | 7,891 |
| 30 Jun 19 | 53,656 | 12,638 | 14,050 | 7,948 |
| 31 Mar 19 | 53,859 | 11,464 | 14,004 | 7,914 |
| 31 Dec 18 | 40,825 | 3,824 | 12,149 | 7,713 |
| 30 Sep 18 | 53,373 | 23,808 | 14,481 | 7,827 |
| 01 Jul 18 | 53,244 | 22,545 | 14,492 | 7,686 |
| 01 Apr 18 | 52,673 | 21,746 | 14,509 | 7,673 |
| 31 Dec 17 | 52,546 | 21,305 | 14,606 | 7,645 |
| 01 Oct 17 | 52,471 | 9,791 | 14,546 | 7,843 |
| 02 Jul 17 | 52,347 | 8,308 | 14,608 | 7,861 |
| 02 Apr 17 | 52,598 | 7,281 | 14,959 | 7,826 |
| 31 Dec 16 | 52,824 | 7,198 | 14,894 | 7,858 |
| 02 Oct 16 | 53,243 | 6,270 | 14,956 | 7,652 |
| 03 Jul 16 | 52,286 | 7,036 | 14,697 | 7,797 |
| 03 Apr 16 | 50,992 | 7,615 | 14,339 | 7,787 |
| 31 Dec 15 | 48,851 | 6,948 | 14,325 | 7,646 |
| 27 Sep 15 | 47,922 | 8,366 | 13,640 | 7,366 |
| 28 Jun 15 | 48,196 | 8,913 | 13,666 | 7,135 |
| 29 Mar 15 | 49,116 | 9,200 | 13,776 | 7,118 |
| 31 Dec 14 | 49,605 | 9,085 | 13,720 | 7,150 |
| 28 Sep 14 | 50,045 | 10,461 | 13,894 | 6,902 |
| 29 Jun 14 | 50,327 | 10,370 | 13,944 | 6,740 |
| 30 Mar 14 | 50,527 | 10,994 | 14,009 | 6,546 |
| 31 Dec 13 | 51,584 | 11,339 | 14,164 | 6,551 |
| 29 Sep 13 | 51,917 | 10,185 | 14,345 | 6,398 |
| 30 Jun 13 | 52,227 | 10,590 | 14,436 | 6,612 |
Quality Earnings: PFE has a large one-off loss of $6.0B impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: PFE's current net profit margins (3.6%) are lower than last year (31.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PFE's earnings have grown by 19.4% per year over the past 5 years.
Accelerating Growth: PFE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PFE had negative earnings growth (-93.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-6.8%).
Return on Equity
High ROE: PFE's Return on Equity (2.4%) is considered low.